Method of diagnosis, prognosis or treatment of neurodegenerative diseases
a neurodegenerative disease and prognostic technology, applied in the field of neurodegenerative diseases diagnosis, prognosis or treatment, can solve the problems of severe debilitating effect on patient's life, disease constitutes an enormous health, social and economic burden, complete erosion of higher cognitive function, etc., to achieve the effect of reducing the level of phosphorylation of protein tau
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Image
Examples
example 1
sue Dissection from Control and AD Human Brain Tissue
[1014]Post-mortem human brain sampling was performed according to the Consortium to Establish a Registry of AD (CERAD). Two experimental groups were included in the study, an aged group (n=8, control group) with subject ages ranging from 60 to 77 years with a mean of 67.8±2.9 years, and an AD group (n=8) with subjects ages ranging from 69 to 82 years with a mean of 76.8±3.5 years. Subjects included in the study received post-mortem evaluation by a board-certified neuropathologist. Post-mortem intervals varied from 8.0 h to 15.2 h for both groups. No significant statistical difference (p=0.1781) was found for post-mortem delay between the two groups. Brains were obtained at autopsy and halved sagitally within 2 h after autopsy. One hemisphere was cut into 2-cm-thick slabs along the frontal plane from which the hippocampus (temporal lobe), cortex, and cerebellum were dissected. Tissues were immediately frozen after dissection in dry...
example 2
aques and Neurofibrillary Tangles (NFT) Quantification in Control and AD Human Brain Tissue
[1015]Neuropathologic changes in brains were investigated using Consortium to Establish a Registry for Alzheimer's Disease (CERAD) and Braak and Braak guidelines. Senile plaques and NFT were determined on Bielschowsky—stained sections of middle frontal gyms, middle temporal gyrus, inferior parietal lobule, occipital pole, hippocampal CA1 and enthorinal cortex. Senile plaques were counted using a 10× objective and NFT were counted with a 20× objective. An arithmetic mean was calculated (Mean±SEM) from the counts of six fields for senile plaques / mm2 and NFT / mm2 for each region. Neuropathologic diagnosis was then made using the guidelines proposed by CERAD and Braak and Braak criteria. AD brains were characterized to be at stage III-V from hippocampal analysis. Control brains were determined to be non AD.
example 3
tochemical HS and Tau Co-Localization on Human Hippocampus
[1016]Sections (20 μm) of human hippocampus from Alzheimer and age-matched control were fixed with 3% acetic acid for 10 min at room temperature (rt). Sections were then incubated for 30 min with 3% BSA dissolved in phosphate-buffered saline (PBS) and permeabilized with 0.2% Triton X100 in PBS for 30 min. HS were stained with an anti-heparan sulfate (10E4 epitope, Seikagaku corp. by AMS Biotechnology) and anti-Tau phosphoSerine 262 (Millipore); dissolved in permeabilization buffer (1:200) and incubated for 1 h 30 min at rt. Fluorescence was introduced by staining tissue slides with a secondary antibody conjugated to an Alexa 568 fluoroprobe (Molecular Probes) and Alexa 488 fluoroprobe (Interchim). Then, sections were DAPI labelled for 3 min with a 1 μg / mL DAPI solution and rinsed with methanol. Images were first obtained using a CCD monochrome camera (CFW-1310M, Scion Corporation, USA) fitted to a BH-2 epi-fluorescence optica...
PUM
| Property | Measurement | Unit |
|---|---|---|
| Mass | aaaaa | aaaaa |
| Mass | aaaaa | aaaaa |
| Mass | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More